Ironwood Pharmaceuticals ... (IRWD)
Ironwood Pharmaceuticals Statistics
Share Statistics
Ironwood Pharmaceuticals has 161.81M shares outstanding. The number of shares has increased by 0.67% in one year.
| Shares Outstanding | 161.81M |
| Shares Change (YoY) | 0.67% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 156.66M |
| Failed to Deliver (FTD) Shares | 50 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 11.64M, so 7.28% of the outstanding shares have been sold short.
| Short Interest | 11.64M |
| Short % of Shares Out | 7.28% |
| Short % of Float | 14.06% |
| Short Ratio (days to cover) | 2.25 |
Valuation Ratios
The PE ratio is 800.84 and the forward PE ratio is 4.25. Ironwood Pharmaceuticals's PEG ratio is -8.
| PE Ratio | 800.84 |
| Forward PE | 4.25 |
| PS Ratio | 2.01 |
| Forward PS | 0.4 |
| PB Ratio | -2.34 |
| P/FCF Ratio | 6.82 |
| PEG Ratio | -8 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Ironwood Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.69, with a Debt / Equity ratio of -1.99.
| Current Ratio | 4.69 |
| Quick Ratio | 4.69 |
| Debt / Equity | -1.99 |
| Debt / EBITDA | 5.98 |
| Debt / FCF | 5.8 |
| Interest Coverage | 2.82 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.39M |
| Profits Per Employee | $3.48K |
| Employee Count | 253 |
| Asset Turnover | 1 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 64.32M |
| Effective Tax Rate | 98.65% |
Stock Price Statistics
The stock price has increased by -88.8% in the last 52 weeks. The beta is 0.3, so Ironwood Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.3 |
| 52-Week Price Change | -88.8% |
| 50-Day Moving Average | 1.3 |
| 200-Day Moving Average | 3.52 |
| Relative Strength Index (RSI) | 39.58 |
| Average Volume (20 Days) | 3.92M |
Income Statement
In the last 12 months, Ironwood Pharmaceuticals had revenue of 351.41M and earned 880K in profits. Earnings per share was 0.01.
| Revenue | 351.41M |
| Gross Profit | 349.4M |
| Operating Income | 93.12M |
| Net Income | 880K |
| EBITDA | 100.24M |
| EBIT | 98.23M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 88.56M in cash and 599.48M in debt, giving a net cash position of -510.92M.
| Cash & Cash Equivalents | 88.56M |
| Total Debt | 599.48M |
| Net Cash | -510.92M |
| Retained Earnings | -1.7B |
| Total Assets | 350.91M |
| Working Capital | 143.52M |
Cash Flow
In the last 12 months, operating cash flow was 103.55M and capital expenditures -142K, giving a free cash flow of 103.41M.
| Operating Cash Flow | 103.55M |
| Capital Expenditures | -142K |
| Free Cash Flow | 103.41M |
| FCF Per Share | 0.65 |
Margins
Gross margin is 99.43%, with operating and profit margins of 26.5% and 0.25%.
| Gross Margin | 99.43% |
| Operating Margin | 26.5% |
| Pretax Margin | 18.55% |
| Profit Margin | 0.25% |
| EBITDA Margin | 28.53% |
| EBIT Margin | 26.5% |
| FCF Margin | 29.43% |
Dividends & Yields
IRWD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for IRWD is $1, which is 7.5% higher than the current price. The consensus rating is "Hold".
| Price Target | $1 |
| Price Target Difference | 7.5% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Apr 2, 2019. It was a forward split with a ratio of 597:500.
| Last Split Date | Apr 2, 2019 |
| Split Type | forward |
| Split Ratio | 597:500 |
Scores
| Altman Z-Score | -4.21 |
| Piotroski F-Score | 7 |